Table 4 Type of drug-related actions where the patient provided additional essential information during medication reconciliation (MR). The table shows the proportions of outpatient visits (n = 83) with additional essential information provided by the patient during MR sorted by the type of drug-related action. The proportions were determined based on the required drug information indicated by the rheumatologists and expert panel
Type of drug-related action | Number of visits with requirement of drug information for certain type of action | Proportion of visits in which patient’s interview during MR provided additional essential information available compared to: | ||||
|---|---|---|---|---|---|---|
EMR, N (%) | EMR plus NMRS, N (%) | |||||
Rheumatologists | Expert panel | Rheumatologists | Expert panel | Rheumatologists | Expert panel | |
Drug changes | ||||||
 Start a drug (n = 24) | 8 | 13 | 3 (38) | 7 (54) | 0 (0) | 1 (8) |
 Stop a drug (n = 23) | 11 | 22 | 3 (27) | 4 (18) | 0 (0) | 0 (0) |
 Change frequency of current drug (n = 13) | 6 | 13 | 1 (17) | 3 (23) | 0 (0) | 2 (15) |
 Change strength of current drug (n = 6) | 3 | 6 | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
 Change dosage form of current drug (n = 1) | 1 | 1 | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
Total drug changes (n = 67) |  |  |  |  |  |  |
'DRPs | ||||||
Drug selection (n = 19) | 4 | 14 | 0 (0) | 7 (50) | 0 (0) | 5 (36) |
Dosing problems (n = 1) | 1 | 1 | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
Compliance (n = 5) | 1 | 2 | 0 (0) | 1 (50) | 0 (0) | 0 (0) |
Untreated indications (n = 0) | 0 | 0 | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
Monitoring (n = 1) | 1 | 1 | 0 (0) | 1 (100) | 0 (0) | 1 (100) |
Education or information (n = 8) | 0 | 6 | 0 (0) | 1 (17) | 0 (0) | 1 (100) |
Non-clinical (n = 0) | 0 | 0 | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
Toxicity or adverse reaction n = 22) | 6 | 17 | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
Total DRPs (n = 56) |  |  |  |  |  |  |
Total drug changes and DRPs (n = 123) |  |  |  |  |  |  |